ADLR Skyrockets 143%
Cubist to Buy Adolor in Potential $415M Deal
By Marie Powers
Tuesday, October 25, 2011
Cubist Pharmaceuticals Inc., which focuses on the development of drugs to combat conditions prevalent in the hospital setting, will expand its product pipeline with the acquisition of Adolor Corp. in a deal potentially valued at $415 million.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.